Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of an IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

NCT05843448 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT05843448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05843448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of an IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
Lead sponsor
University of California, Davis
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 19, 2023
Completion date
December 31, 2026
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high risk non-muscle invasive bladder urothelial carcinoma, stage 0a bladder cancer ajcc v8, stage 0is bladder cancer ajcc v8, stage i bladder cancer ajcc v8